Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Brilinta Boost For AZ In Stroke Study

Outperforms Aspirin Alone In 11,000-Patient Trial

28 Jan 2020

• By Kevin Grogan

Red_Wire — Stroke is second leading cause of death worldwide • Source: Shutterstock

Related Content

Brilinta No Better Than Aspirin In Stroke Trial

24 Mar 2016

Game over as AstraZeneca rejects final $119bn Pfizer bid

19 May 2014

AstraZeneca Says $3.5bn Brilinta Sales Forecast By 2023 Now Unattainable

04 Oct 2016

AstraZeneca's Dobber On Ramping In Renal, Expanding In CV And Business Development

21 Jan 2020

AZ’s Farxiga Gets FDA Priority Review For Heart Failure

06 Jan 2020

AstraZeneca Aiming To Extend Brilinta Use In PCI patients

02 Sep 2019

AstraZeneca Makes Case For Independence With $23 Bil. Pipeline Potential

06 May 2014

Related Companies

AstraZeneca PLC

Additional Topics

Clinical Trials Research & Development Cardiovascular BioPharmaceutical

More from Cardiovascular

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.